✦ LIBER ✦

BRCA1—A good predictive marker of drug sensitivity in breast cancer treatment?

✍ Scribed by Paul B. Mullan; Julia J. Gorski; D. Paul Harkin

Book ID: 113486635
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 758 KB
Volume: 1766
Category: Article
ISSN: 0304-419X
DOI: 10.1016/j.bbcan.2006.07.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Promoter methylation of BRCA1 in triple-

Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy

✍ Xu, Y.; Diao, L.; Chen, Y.; Liu, Y.; Wang, C.; Ouyang, T.; Li, J.; Wang, T.; Fan 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 290 KB

BRCA1: A new marker in the management of

BRCA1: A new marker in the management of patients with breast cancer?

✍ Kenneth Offit 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB 👁 2 views

Expression of the stem cell marker ALDH1

Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer

✍ Marise R. Heerma van Voss; Petra van der Groep; Joost Bart; Elsken van der Wall; 📂 Article 📅 2011 🏛 Springer Netherlands 🌐 English ⚖ 247 KB

Loss of heterozygosity in BRCA1 and BRCA

Loss of heterozygosity in BRCA1 and BRCA2 markers and high‐grade malignancy in breast cancer

✍ Jose M. Silva; Rocio Gonzalez; Mariano Provencio; Gema Dominguez; Jose M. Garcia 📂 Article 📅 1999 🏛 Springer US 🌐 English ⚖ 87 KB

Opportunities and hurdles in the treatme

Opportunities and hurdles in the treatment of BRCA1-related breast cancer

✍ Drost, R; Jonkers, J 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 650 KB

Survival of breast cancer patients in BR

Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from Finland

✍ Hannaleena Eerola; Pia Vahteristo; Laura Sarantaus; Pentti Kyyrönen; Seppo Pyrhö 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 69 KB 👁 1 views

Reports on the prognosis of familial breast cancer patients have been contradictory. True differences in survival, if they exist, would have important implications for genetic counselling and in treatment of hereditary breast cancer. We assessed the survival rates of 359 familial breast cancer patie